Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of an investigational
medication, axitinib, to radiation therapy will improve the outcome of treatment in patients,
above the age of 70.